Compare Vanguard Mega Cap Growth ETF (MGK) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard Mega Cap Growth ETF vs Viatris Inc — how do they compare? Vanguard Mega Cap Growth ETF trades at $87.63, while Viatris Inc trades at $17.54 (market cap $19.79B). The key difference: Viatris Inc pays a 2.83% dividend while Vanguard Mega Cap Growth ETF pays none, and Viatris Inc is trading nearer its 52-week high, Vanguard Mega Cap Growth ETF nearer its low. Which is the better fit depends on your goals.
| MGK | VTRS | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $92.06 | $17.39 |
52-Week Low | $70.70 | $8.74 |
Market Cap | — | $19.79B |
Enterprise Value | — | $32.00B |
Dividend Yield | — | 2.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MGK, the Vanguard Mega Cap Growth ETF, trades at $86.83 with no recent price change. Technical indicators show a bearish bias, with moving averages signaling caution and oscillators neutral. The fund's concentrated portfolio of 69 large-cap growth stocks, including heavy tech exposure, offers strong historical returns but elevated concentration risk. Recent news highlights its low 0.05% expense ratio and potential inclusion of SpaceX, adding momentum to its growth narrative.
Outlook remains tied to mega-cap tech performance, with opportunities for long-term growth driven by earnings momentum. Risks include sector concentration, valuation sensitivity, and market volatility. Investors should weigh the ETF's cost efficiency against its narrow focus.
Viatris (VTRS) trades at $17.59, up 1.74% today, with a bullish technical signal and consistent earnings beats in recent quarters. The company reported revenue of $14.3B for 2025 but posted a net loss of $3.51B, reflecting margin pressures. Positive pipeline developments include FDA acceptance of a new drug application for fast-acting meloxicam, with a PDUFA date set for December 2026. Cash flow from operations remains strong at $2.32B, supporting debt reduction efforts.
The outlook is mixed: analyst consensus targets $20.00 (13.7% upside), but profitability challenges and high debt levels pose risks. Investment appeal hinges on successful pipeline execution and margin recovery, while competitive and regulatory pressures in the generics market remain key watchpoints for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Vanguard Mega Cap Growth ETF
MGK is an ETF that seeks to track the performance of the CRSP US Mega Cap Growth Index. It provides a low-cost, diversified exposure to the largest growth companies in the U.S. stock market. The fund is composed of mega-cap stocks that exhibit key growth factors, including high expected long-term earnings growth, high historical sales and earnings growth, and high return on assets. MGK is typically used by investors seeking long-term capital appreciation from market-leading firms.
Read more on MGK →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
